Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) is pleased to announce the first procedures using the Company’s products following CE mark of the Vision-MR Ablation Catheter have been performed at the Heart Center Dresden.
Imricor Medical Systems, Inc. (ASX:IMR) today announces that it has received CE mark approval for its Vision-MR Ablation Catheter and Vision-MR Dispersive Electrode. This follows earlier CE mark approval for Imricor to place its Advantage-MR EP Recorder/Stimulator System on the market in the European Union. Imricor is the first and only company to offer cardiac ablation in the MRI environment.
Imricor announced today that it signed its first commercialization contract in the Netherlands with the Amsterdam University Medical Center, location VUmc, for the Advantage-MR™ EP Recorder/Stimulator System. With this agreement, Amsterdam UMC will become the first Dutch site to install the Advantage-MR system and perform real-time MRI-guided cardiac ablations, placing them at the forefront of clinical adoption for interventional cardiac magnetic resonance (iCMR) electrophysiology procedures.
Imricor announced today that it signed its first commercialization contract for the Advantage-MR EP Recorder/Stimulator System and supporting Vision-MR devices1 with the Heart Center Dresden in Germany. This agreement places the Heart Center Dresden at the forefront of clinical advancement for MRI-guided cardiac ablations and establishes the hospital as a world leader in the growing field of interventional cardiac magnetic resonance (iCMR).
Imricor Medical Systems announced today the completion of enrollment for the clinical study to evaluate Imricor’s Vision-MR™ Ablation Catheter for the treatment of atrial flutter under real-time MRI guidance. The single-center study enrolled 35 patients and was sponsored by the University of Leipzig Heart Center in Leipzig, Germany. Professor Gerhard Hindricks MD, Head of the Department of Electrophysiology at the Leipzig Heart Center, was the principal investigator.
Imricor Medical Systems announced that it has been awarded a contract for up to $2.4 million from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) to develop an MR compatible injection catheter for MRI-guided procedures. This ten month contract which has a two-year option period will support the continued advancement of real-time MRI guided interventions for the treatment of cardiac arrhythmias.
Imricor and MiRTLE Medical announce a joint development agreement to fully integrate MiRTLE’s MR compatible 12-lead ECG system with Imricor’s Advantage-MRTM EP Recorder/Stimulator System. This integration, along with Imricor’s MR compatible catheters, will allow physicians to perform complex cardiac ablations, such as for treating ventricular tachycardia and atrial fibrillation, under real-time MRI-guidance.
Siemens Healthineers is joining forces with U.S.-based Imricor Medical Systems Inc. to develop an integrated solution that combines the clinical benefits of real-time MRI scans with 3D-guided cardiac ablation. The companies’ shared goal is the development of MRI-compatible devices that translate information on cardiac conduction, morphological substrates, and individual patient anatomy into better treatment outcomes. This approach will potentially enable electrophysiologists to treat heart arrhythmia without radiation and to use the visualization of soft tissue information obtained through MRI.